Bantam Pharmaceutical

Bantam Pharmaceutical, led by President and CEO Michael Stocum, is a biopharmaceutical company focused on discovering and developing novel small-molecule therapies for difficult-to-treat hematologic malignancies and solid tumors. The company's current clinical development strategy centers on B-cell hematologic malignancies, with plans to expand to other patient populations based on responses from biomarker-selected groups.BTM-3566 is a novel selective modulator of mitochondrial dynamics, targeting pathways involved in mitochondrial homeostasis, which specifically drive cancer cell apoptosis in many tumor types with unmet needs. The company utilizes protein transformation phenotypic screening to discover its clinical candidates and related compounds.